← boardnext 2026-11-30next 2027-11-15
AURA
Aura Biosciencesdistress 6/10 · elevated risk$6.990%today-22% from 52w high
Lead: early choroidal melanoma · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$85M
Runway
0.9 yrs
Shares 1y
+66%
Price & events
+21.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
+1.4%
1W
-0.5%
1M
-3.8%
3M
+23.0%
6M
-0.2%
1Y
-26.0%
2Y
—
5Y
-52.8%
All
Overview
- Market Cap
- $722.16M
- Volume
- 12.50K
- 52 Week Range
- $4.97 – $8.90
- Total Shares
- 103.39M
- Float Shares
- 93.30M
- Short %
- 6.75%
- % Held by Insiders
- 1.16%
- % Held by Institutions
- 49.36%
- RVOL
- 0.02x
- Beta
- 0.40
Pipeline stages · 2 programs
AU-011
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Bel-sar
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-30 Estimated 50% readout ~2027-01-14 | Phase 2 | AU-011 | Eye Cancer, Primary Cancer | — | recruiting |
| 2027-03 Estimated 50% readout ~2027-03-31 | Phase 1 | AU-011 | Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder | — | recruiting |
| 2027-11-15 Estimated 50% readout ~2028-01-29 | Phase 3 | Bel-sarorphanfast track | Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma | — | recruiting |
Catalyst news & presentations · 8
- Q4 2027Guided 70%readoutPhase 3bel-sar · Topline data readout for 15-month primary endpoint.SEC 8-K
- 2026Guided 40%enrollment completesecondaryPhase 3bel-sar · Enrollment completion guidance for Phase 3 CoMpass trial.SEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- mid-2026enrollment completesecondaryPhase 3bel-sar · CoMpass trial enrollment completionSEC 8-K
- Mid-2026readoutPhase 1/2bel-sar · Data readout for Phase 1b/2 trial.SEC 8-K
- 2025readoutPhase 2bel-sar · Initial data from Phase 2 trialSEC 8-K
- October 2024conferencedata presentationsecondaryPhase 1bel-sar · Early NMIBC data from ongoing Phase 1 trial presented at urologic oncology investor event.SEC 8-K
- September 11-15, 2024conferencedata presentationsecondaryPhase 2bel-sar · Phase 2 end of study data for small choroidal melanoma at Retina Society Annual Meeting.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-29HC Wainwright & Co.Buy
- 2026-03-30HC Wainwright & Co.Buy
- 2025-08-13HC Wainwright & Co.Buy
- 2025-05-23JMP SecuritiesMarket Outperform
- 2025-03-26JMP SecuritiesMarket Outperform
- 2025-03-26Citizens Capital MarketsMarket Outperform
Competitors — early choroidal melanoma
- none identified
Recent news
- 2026-07-17The Technical Signals Behind (AURA) That Institutions Follow - Stock Traders Daily
- 2026-07-14Price to earnings forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
- 2026-07-08Form 4 Aura Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria
- 2026-07-08Aura Biosciences (NASDAQ: AURA) files initial Form 3 for director Jeremy Bender - Stock Titan
- 2026-07-08Aura Biosciences (AURA) director receives RSU and 60,000 stock option grant - Stock Titan
- 2026-07-08Jeremy Bender joins Aura Biosciences (NASDAQ: AURA) board as independent director - Stock Titan
- 2026-07-08Aura Biosciences adds biotech veteran Bender as bel-sar nears approval - Stock Titan
- 2026-07-05The Technical Signals Behind (AURA) That Institutions Follow - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.